SCHEDULE: Great Point Partners Discloses 6.24% Stake in Unicycive
Beneficial Ownership Report
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a 6.24% beneficial ownership stake in Unicycive Therapeutics, Inc.
Summary
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 796,558 shares of Unicycive Therapeutics, Inc. Common Stock.
- This ownership represents 6.24% of Unicycive Therapeutics, Inc.'s outstanding common stock.
- The percentage is based on 12,768,239 shares outstanding, as reported by Unicycive Therapeutics, Inc. in its Form 8-K filed on June 20, 2025.
- Great Point Partners, LLC serves as the investment manager for Biomedical Value Fund, L.P. (BVF) and Biomedical Offshore Value Fund, Ltd. (BOVF).
- BVF holds 510,494 shares and BOVF holds 286,064 shares of Unicycive Common Stock.
- Dr. Jeffrey R. Jay, M.D., as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point Partners, LLC, have shared voting and dispositive power over these shares.
- The reporting persons disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests.
- The shares were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory update.
Future Outlook
This filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing indicates a significant institutional investment firm, Great Point Partners, maintains a substantial stake in Unicycive Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector. Such ownership by specialized investment firms can signal confidence in the company's long-term prospects or specific therapeutic pipelines, aligning with broader trends of targeted investments in life sciences.
Related Party Transactions
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have entered into a Joint Filing Agreement to file this statement jointly.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Great Point Partners, LLC, a specialized investment firm, may be viewed positively by other shareholders as a vote of confidence in Unicycive Therapeutics, Inc. It also clarifies the ownership structure and control dynamics.
- Investment Professionals: Provides transparency on institutional holdings, which can influence investment decisions and market perception.
Key Dates
| Date | Description |
|---|---|
| 2025-06-20 | Date Unicycive Therapeutics, Inc. filed Form 8-K reporting 12,768,239 shares outstanding, used as the basis for percentage calculation. |
| 2025-06-30 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-08-14 | Date of the Joint Filing Agreement between the reporting persons and the filing date of this Schedule 13G. |
Keywords
Unicycive Therapeutics, Great Point Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.